

DP.1. Control tables

Data inclusion criteria

Report year: 2016

Country: Lithuania

EU Submission: ALL

Genetic status: ALL

Animal Species: ALL

Species grouping Level 1: ALL

Species grouping Level 2: ALL

Mammals: ALL

Non-human primates: ALL

Creation of New GL: ALL

Purpose Category level 1: ALL

Purpose Category level 2: ALL

Purpose Category level 3: ALL

Purpose Category level 4: ALL

Re-use: ALL

Place of Birth: ALL

NHP Generation: ALL

NHP Source (origin): ALL

Legislative Requirement: ALL

Testing by Legislation: ALL

Severity: ALL

Submission Id: ALL

Id 1: ALL

Id 2: ALL

Id 3: ALL

Narrative

This report shows the total number of uses in all of the harmonised reported categories, including for non-EU submissions (unless specifically excluded). It provides at a glance information facilitating quality control of submitted data by highlighting e.g. especially high use of 'other' columns, or any other unusual use patterns.

The findings from this report provide a first line of alert for potential problems in data quality.

With the use of other Data Provider control reports, more detailed information can be elicited, narrowing down a potential problem to the level of National ID1/2/3s and EC (submission) ID (from DECLARE). With the help of Custom IDs and EC ID (submission) from DECLARE, the erroneous submission can quickly be identified and corrected.

The report does not include free text fields.

DP.1. Control tables

EU Submission	Number of uses	Percentage
Yes	2,660	100.00%
No		
Total uses	2,660	100.00%

Re-Use	Number of uses	Percentage
No	2,660	100.00%
Yes		
Total uses	2,660	100.00%

Creation of New GL	Number of uses	Percentage
No	2,660	100.00%
Yes		
Total uses	2,660	100.00%

Genetic Status	Number of uses	Percentage
Not genetically altered	2,660	100.00%
Genetically altered without a harmful phenotype	0	0.00%
Genetically altered with a harmful phenotype		
Total uses	2,660	100.00%

Severity	Number of uses	Percentage
Non-recovery	238	8.95%
Mild [up to and including]	1,812	68.12%
Moderate	610	22.93%
Severe		
Total uses	2,660	100.00%

Animal Species	Number of uses	Percentage
Mice	1,759	66.13%
Rats	744	27.97%
Guinea-Pigs	30	1.13%
Hamsters (Syrian)		
Hamsters (Chinese)		
Mongolian gerbil		
Other Rodents		
Rabbits	51	1.92%
Cats		
Dogs		
Ferrets		
Other carnivores		
Horses, donkeys & cross-breeds		
Pigs	48	1.80%
Goats		
Sheep	28	1.05%
Cattle		
Prosimians		
Marmoset and tamarins		
Cynomolgus monkey		
Rhesus monkey		
Vervets Chlorocebus spp.		
Baboons		
Squirrel monkey		
Other species of New World Monkeys (Ceboidea)		
Other species of Old World Monkeys (Cercopithecoidea)		
Other species of non-human primates		
Apes		
Other Mammals		
Domestic fowl		
Other birds		
Reptiles		
Rana		
Xenopus		
Other Amphibians		
Zebra fish		
Other Fish		
Cephalopods		
Total uses	2,660	100.00%

Rodents	Percentage
Mice	69.44%
Rats	29.37%
Guinea-Pigs	1.18%
Hamsters (Syrian)	
Hamsters (Chinese)	
Mongolian gerbil	
Other Rodents	

Carnivores	Percentage
Cats	
Dogs	
Ferrets	
Other carnivores	

New world monkeys	Percentage
Marmoset and tamarins	
Squirrel monkey	
Other species of New World Monkeys (Ceboidea)	

Old world monkeys	Percentage
Cynomolgus monkey	
Rhesus monkey	
Vervets Chlorocebus spp.	
Baboons	
Other species of Old World Monkeys (Cercopithecoidea)	

Birds	Percentage
Domestic fowl	
Other birds	

Fish	Percentage
Zebra fish	
Other Fish	

Amphibians	Percentage
Rana	
Xenopus	
Other Amphibians	

DP.1. Control tables

Species grouping Level 1	Number of uses	Percentage
Warm-blooded vertebrates	2,660	100.00%
Cold-blooded vertebrates		
Invertebrates		
Total uses	2,660	100.00%

Species grouping Level 2	Number of uses	Percentage
Mammals	2,660	100.00%
Birds		
Fish		
Amphibians		
Reptiles		
Cephalopods		
Total uses	2,660	100.00%

Mammals	Number of uses	Percentage
Rodents	2,533	95.23%
Rabbits	51	1.92%
Carnivores		
Equidae		
Artiodactyla	76	2.86%
Non-human primates		
Other mammals		
Total uses	2,660	100.00%

Non-human primates	Number of uses	Percentage
Prosimians		
New World Monkeys		
Old World Monkeys		
Apes		
Total uses		

Place of Birth	Number of uses	Percentage
Animals born in the EU at a registered breeder	2,602	97.82%
Animals born in the EU but not at a registered breeder	58	2.18%
Animals born in rest of Europe		
Animals born in rest of world		
Total uses	2,660	100.00%

NHP Source (origin)	Number of uses	Percentage
Animals born at a registered breeder within EU		
Animals born in rest of Europe		
Animals born in Asia		
Animals born in America		
Animals born in Africa		
Animals born elsewhere		
Total uses		

NHP Generation	Number of uses	Percentage
F0		
F1		
F2 or greater		
Self-sustaining colony		
Total uses		

DP.1. Control tables

Purpose Category level 1	Number of uses	Percentage
Basic Research	2,212	83.16%
Translational and applied research	117	4.40%
Regulatory use and Routine production	230	8.65%
Protection of the natural environment in the interests of the health or welfare of human beings or animals		
Preservation of species		
Higher education or training for the acquisition, maintenance or improvement of vocational skills	101	3.80%
Forensic enquiries		
Maintenance of colonies of established genetically altered animals, not used in other procedures		
Non-EU Purpose		
Total uses	2,660	100.00%

Testing by Legislation	Number of uses	Percentage
Legislation on medicinal products for human use	175	76.09%
Legislation on medicinal products for veterinary use and their residues	55	23.91%
Medical devices legislation		
Industrial chemicals legislation		
Plant protection product legislation		
Biocides legislation		
Food legislation including food contact material		
Feed legislation including legislation for the safety of target animals, workers and environment		
Cosmetics legislation		
Other legislation		
Total uses	230	100.00%

Legislative Requirement	Number of uses	Percentage
Legislation satisfying EU requirements	230	100.00%
Legislation satisfying national requirements only [within EU]		
Legislation satisfying Non-EU requirements only		
Total uses	230	100.00%

DP.1. Control tables

Basic Research	Number of uses	Percentage
Oncology	567	25.63%
Cardiovascular Blood and Lymphatic System	58	2.62%
Nervous System	69	3.12%
Respiratory System		
Gastrointestinal System including Liver		
Musculoskeletal System	534	24.14%
Immune System	248	11.21%
Urogenital/Reproductive System	214	9.67%
Sensory Organs (skin, eyes and ears)		
Endocrine System/Metabolism	400	18.08%
Multisystemic	122	5.52%
Ethology / Animal Behaviour /Animal Biology		
Other basic research		
Total uses	2,212	100.00%

Translational and applied research	Number of uses	Percentage
Human Cancer		
Human Infectious Disorders		
Human Cardiovascular Disorders	18	15.38%
Human Nervous and Mental Disorders		
Human Respiratory Disorders		
Human Gastrointestinal Disorders including Liver		
Human Musculoskeletal Disorders		
Human Immune Disorders		
Human Urogenital/Reproductive Disorders		
Human Sensory Organ Disorders (skin, eyes and ears)	27	23.08%
Human Endocrine/Metabolism Disorders		
Other Human Disorders		
Animal Diseases and Disorders		
Animal Welfare		
Diagnosis of diseases		
Plant diseases		
Non-regulatory toxicology and ecotoxicology	72	61.54%
Total uses	117	100.00%

DP.1. Control tables

Regulatory use and routine Production	Number of uses	Percentage
Quality control (incl batch safety and potency testing)		
Quality control (incl batch safety and potency testing)		
Quality control (incl batch safety and potency testing)		
Quality control (incl batch safety and potency testing)		
Other efficacy and tolerance testing		
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Toxicity and other safety testing including pharmacology	95	41.30%
Routine production	135	58.70%
Routine production	135	58.70%
Routine production	135	58.70%
Total uses	230	1,250.00%

DP.1. Control tables

Regulatory use and routine production – Routine production	Number of uses	Percentage
Blood based products	135	100.00%
Monoclonal antibodies		
Other product types		
Total uses	135	100.00%

Regulatory use and routine production – Quality control (incl batch safety and potency testing)	Number of uses	Percentage
Batch safety testing		
Pyrogenicity testing		
Batch potency testing		
Other quality controls		
Total uses		

DP.1. Control tables

Regulatory use and routine production - Toxicity and other safety testing including pharmacology	Number of uses	Percentage
Acute and sub-acute	40	42.11%
Acute and sub-acute	40	42.11%
Acute and sub-acute	40	42.11%
Skin irritation/corrosion		
Skin sensitisation	15	15.79%
Eye irritation/corrosion		
Repeated dose toxicity		
Repeated dose toxicity		
Repeated dose toxicity		
Carcinogenicity		
Genotoxicity		
Reproductive toxicity		
Developmental toxicity		
Neurotoxicity		
Kinetics		
Pharmaco-dynamics (incl safety pharmacology)	40	42.11%
Phototoxicity		
Ecotoxicity		
Ecotoxicity		
Ecotoxicity		
Ecotoxicity		
Ecotoxicity		
Ecotoxicity		
Safety testing in food and feed area		
Target animal safety		
Other toxicity/safety testing		
Total uses	95	184.21%

Regulatory use and routine production – Toxicity and other safety testing including pharmacology – Repeated dose toxicity	Number of uses	Percentage
up to 28 days		
29 - 90 days		
> 90 days		
Total uses		

DP.1. Control tables

Regulatory use and routine production – Toxicity and other safety testing including pharmacology – Acute and sub-acute toxicity testing methods	Number of uses	Percentage
LD50, LC50		
Other lethal methods		
Non lethal methods	40	100.00%
Total uses	40	100.00%

Regulatory use and routine production – Toxicity and other safety testing including pharmacology – Ecotoxicity	Number of uses	Percentage
Acute toxicity		
Chronic toxicity		
Reproductive ecotoxicity		
Endocrine activity		
Bioaccumulation		
Other ecotoxicity		
Total uses		